Name: Cigna Group (NYSE:CI) | Income Statement (Quarterly)
Creator: Stock Analysis on Net

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Download chart

Cigna Group, consolidated income statement (quarterly data)

US$ in millions

3 months ended:	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Pharmacy revenues	49,941)	48,284)	45,101)	42,036)	36,604)	34,531)	33,964)	32,144)	33,135)	32,762)	31,972)	30,697)	32,328)	31,013)	30,047)	28,025)	28,305)	27,802)	26,564)	25,098)
Premiums	11,503)	11,436)	11,454)	11,603)	11,175)	10,998)	11,039)	11,025)	9,547)	9,586)	10,426)	10,356)	10,342)	10,275)	10,323)	10,214)	10,699)	10,682)	10,406)	10,840)
Fees and other revenues	3,928)	3,889)	3,647)	3,326)	3,045)	3,198)	3,305)	3,071)	2,857)	2,728)	2,757)	2,538)	2,638)	2,532)	2,451)	2,341)	2,337)	2,174)	2,072)	2,178)
Revenues from external customers	65,372)	63,609)	60,202)	56,965)	50,824)	48,727)	48,308)	46,240)	45,539)	45,076)	45,155)	43,591)	45,308)	43,820)	42,821)	40,580)	41,341)	40,658)	39,042)	38,116)
Pharmacy and other service costs	(49,021)	(47,565)	(44,492)	(41,431)	(35,261)	(33,639)	(33,442)	(31,459)	(32,094)	(31,777)	(31,150)	(29,813)	(31,247)	(30,070)	(29,001)	(27,235)	(27,059)	(26,624)	(25,611)	(24,190)
Medical costs and other benefit expenses	(10,166)	(9,527)	(9,515)	(9,440)	(9,280)	(8,927)	(9,034)	(9,046)	(7,992)	(7,754)	(8,192)	(8,268)	(8,743)	(8,330)	(8,484)	(8,005)	(8,847)	(8,429)	(7,112)	(8,322)
Gross profit	6,185)	6,517)	6,195)	6,094)	6,283)	6,161)	5,832)	5,735)	5,453)	5,545)	5,813)	5,510)	5,318)	5,420)	5,336)	5,340)	5,435)	5,605)	6,319)	5,604)
Net investment income	277)	85)	321)	290)	290)	321)	278)	277)	212)	204)	325)	414)	380)	468)	310)	391)	371)	297)	223)	353)
Selling, general and administrative expenses	(3,865)	(3,590)	(3,684)	(3,705)	(4,062)	(3,788)	(3,434)	(3,538)	(3,483)	(3,148)	(3,256)	(3,299)	(3,662)	(3,093)	(2,996)	(3,279)	(3,966)	(3,301)	(3,407)	(3,398)
Amortization of acquired intangible assets	(424)	(436)	(420)	(423)	(451)	(454)	(455)	(459)	(457)	(460)	(501)	(458)	(499)	(501)	(503)	(495)	(495)	(493)	(496)	(498)
Income from operations	2,173)	2,576)	2,412)	2,256)	2,060)	2,240)	2,221)	2,015)	1,725)	2,141)	2,381)	2,167)	1,537)	2,294)	2,147)	1,957)	1,345)	2,108)	2,639)	2,061)
Interest expense and other	(362)	(376)	(375)	(322)	(360)	(365)	(363)	(358)	(324)	(304)	(301)	(299)	(293)	(303)	(298)	(314)	(337)	(336)	(374)	(391)
Debt extinguishment costs	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	(10)	(131)	—)	—)	(14)	(185)
Gain (loss) on sale of businesses	130)	(87)	—)	(19)	(1,478)	(21)	—)	—)	(73)	1,735)	—)	—)	—)	—)	—)	—)	4,203)	—)	—)	—)
Net realized investment gains (losses)	68)	(921)	(48)	(1,836)	(34)	(14)	26)	(56)	—)	(81)	(95)	(319)	68)	68)	59)	1)	167)	32)	38)	(88)
Income before income taxes	2,009)	1,192)	1,989)	79)	188)	1,840)	1,884)	1,601)	1,328)	3,491)	1,985)	1,549)	1,312)	2,059)	1,898)	1,513)	5,378)	1,804)	2,289)	1,397)
Income taxes	(473)	(367)	(360)	(291)	919)	(391)	(374)	(295)	(130)	(713)	(413)	(351)	(179)	(424)	(422)	(342)	(1,236)	(406)	(529)	(208)
Net income (loss)	1,536)	825)	1,629)	(212)	1,107)	1,449)	1,510)	1,306)	1,198)	2,778)	1,572)	1,198)	1,133)	1,635)	1,476)	1,171)	4,142)	1,398)	1,760)	1,189)
Net income attributable to noncontrolling interests	(112)	(86)	(81)	(65)	(78)	(41)	(50)	(39)	(29)	(21)	(13)	(15)	(17)	(14)	(9)	(10)	(7)	(10)	(6)	(8)
Shareholders’ net income (loss)	1,424)	739)	1,548)	(277)	1,029)	1,408)	1,460)	1,267)	1,169)	2,757)	1,559)	1,183)	1,116)	1,621)	1,467)	1,161)	4,135)	1,388)	1,754)	1,181)

Total revenues from external customers exhibited a consistent upward trajectory, growing from 38.1 billion US dollars in March 2020 to 65.4 billion US dollars by December 2024. This growth was primarily driven by the pharmacy revenues segment, which nearly doubled from 25.1 billion US dollars to 49.9 billion US dollars over the analyzed period. In contrast, premiums and fees and other revenues showed more moderate growth or stability, with premiums remaining largely range-bound between 9.5 billion and 11.6 billion US dollars.

Cost Structure and Gross Profitability: Pharmacy and other service costs increased in close correlation with pharmacy revenues, rising from 24.2 billion US dollars in March 2020 to 49.0 billion US dollars in December 2024. Medical costs and other benefit expenses remained relatively stable, typically fluctuating between 7.1 billion and 10.2 billion US dollars. Consequently, gross profit remained relatively flat despite the massive increase in top-line revenue, oscillating between 5.3 billion and 6.5 billion US dollars, which indicates tight margins on the expanding pharmacy business.
Operating Expense Management: Selling, general, and administrative expenses remained consistently controlled, generally fluctuating between 2.9 billion and 4.1 billion US dollars per quarter. Amortization of acquired intangible assets also showed minimal variance, staying within the range of 420 million to 503 million US dollars. Income from operations reflects this stability, typically remaining between 1.3 billion and 2.6 billion US dollars, suggesting that operational efficiency has been maintained despite the scaling of revenue.
Non-Operating Volatility and Net Income: Net income and shareholders' net income exhibited significant volatility driven by non-recurring items rather than core operations. Notable spikes occurred in December 2020 and September 2022 due to substantial gains from the sale of businesses, totaling 4.2 billion and 1.7 billion US dollars, respectively. Conversely, net realized investment gains and losses introduced instability, most notably in March 2024, where a realized loss of 1.8 billion US dollars contributed to a shareholders' net loss of 277 million US dollars for that quarter.
Taxation and Interest Trends: Interest expense and other costs remained steady, generally ranging between 293 million and 376 million US dollars. Income tax expenses fluctuated significantly, reflecting the volatility of income before taxes; notably, a tax credit of 919 million US dollars was recorded in December 2023, which deviated from the typical quarterly tax expense pattern.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Cigna Group (NYSE:CI)

Income StatementQuarterly Data

Income Statement
Quarterly Data